EQT Life Sciences and Nextech Invest Ltd are leading Tubulis’ current financing round. numerous existing investors such as Bayern Kapital, Biomedpartners, Coparion, High-Tech Gründerfonds (HTGF), Occident, and Seventure Partners. Two new US investors are also joining the team: Frazier Life Sciences and Deep Track Capital.
The Biotech develops antibody-drug conjugates (ADCs) that can attack cancer cells more specifically than before, without damaging the surrounding tissue. The drug is combined with an antibody that can distinguish cancer cells from healthy cells. This allows ADCs to not only fight cancer more precisely and efficiently, but also significantly reduce the side effects of therapy. Previous ADCs often lost a large portion of their active ingredients before reaching the tumor cell. Tubulis' ADCs deliver these drugs more reliably to their target.
Tubulis plans to use the funds from the current financing round to complete the first clinical evaluation of its two lead ADC candidates, TUB-030 and TUB-040. The money will also be used to further develop Tubulis' technology platform for the development of additional, flexibly adaptable ADCs. Parallel to the entry of the new US investors, Tubulis plans to the startup Furthermore, to expand its corporate presence by establishing a US subsidiary.
"The current financing round from various international investors specializing in the biotech segment further underscores Tubulis' unique positioning in the ADC space. Our proprietary platform technology and expertise form the basis for a pipeline of specialized protein-drug conjugates,"
says Dominik Schumacher, CEO and co-founder of Tubulis.
"Our goal is to establish Tubulis as a global leader in ADC development. Our next step will be to complete the clinical phase to unlock the full power and therapeutic value of ADCs."
